RE:RE:Comments!I also recall when I looked in to what academic articles reviewed anti-CSC and anti-VM that there were no drugs that had proven they could do both. There were a few ongoing trials, but nothing there yet. So if Th1902 can somehow prove up both of these MOA's, it would certainly be unique in that.
qwerty22 wrote: I guess my breakthrough thought earlier was something I read from THTX, then forgot, then"rediscovered" for myself lol.
I'd actually spent a little bit of time trying to find out if either of our favorite two ADCs had any anti-CSC properties. Couldn't find any direct work done in this area for Trodelvy or Erhurtu. So maybe THTX have something extra to brag about over these two leading ADCs. I did discover that trastuzumab, the anti-HER2 antibody that Enhurtu is built on, does have anti-CSC properties. So it seems very possible that Enhurtu is also an anti-CSC drug just no direct research has been done in this area. If that is the alternative case then this too wouldn't be so bad for th1902 as Enhurtu's own anti-CSC activity would likely be contributing to it's attractive drug profile.
An interesting point I picked up from one of the CSC review is that there has generally been a weakness identified in most anti-CSC drugs in development. They target very specific processes in the CSCs. This means that the bulk of the tumour, which are not CSC, remains untouched by these drugs. This makes proving efficacy challenging and makes it more likely these drug must be tested as part of combos which adds another layer of complexity to the trial program. THTX potentially has a drug that can potentially target both the bulk of the tumour and the CSC. That makes it potentially a special case like trastuzumab.
scarlet1967 wrote:
“The development of resistance to chemotherapy is a major obstacle to successful anticancer treatment, and the presence of cancer stem-like cells within tumors is believed to play an important role in that process, said Dr. Christian Marsolais, Chief Medical Officer, Theratechnologies.
Finally, when combined with carboplatin in an ovarian tumor model, the efficacy of TH1902 was also superior to that of paclitaxel- or docetaxel-carboplatin combinations. In TNBC and ovarian CSCs animal models, TH1902 decreased tumor growth by 80%, compared to roughly 35% in docetaxel-treated mouse models.
Given our enhanced understanding of the association of SORT1 and cancer resistance to chemotherapy, using TH1902 to exploit SORT1 function within cancer stem-like cells may further offer a path to bypassing the chemoresistance phenotype often responsible for cancer recurrence, stated Dr. Borhane Annabi, Professor of Biochemistry and Chair in Cancer Prevention and Treatment at UQAM. TH1902 thus appears to offer a promising strategy for targeting cancer cells that exhibit plasticity, metastatic potential, and resistance to chemotherapy.”
https://www.userwalls.news/n/theratechnologies-th1902-study-published-pharmaceutics-demonstrates-inhibition-human-sortilin-sort1-positive-ovarian-3804529/